The clinical usage of the cholinesterase inhibitor tacrine for treatment of Alzheimer's disease is accompanied by adverse effects on the gastrointestinal tract. These adverse effects are a result of the direct action of tacrine on the intestinal smooth muscles or of the modulation of certain neurotransmitters regulating gastrointestinal functions. Dopamine is a neurotransmitter that modulates gastrointestinal motility. This study was designed to examine in vitro the effects of tacrine on dopamine-induced changes in spontaneous activity of smooth muscle preparations from rat's gastric corpus. The mechanical activity was isometrically registered. Tacrine 1.10(-7)-1.10(-5) mol/l caused smooth muscle contraction, which was blocked by atropine 1.10(-6) mol/l. Tacrine 1.10(-4) mol/l provoked a relaxation resistant to atropine. Dopamine and D(2)-receptor antagonists haloperidol and R121 had no effect on tacrine-induced relaxation. Dopamine-induced contraction was concentration-dependent. It was blocked by D(2)-receptor antagonists haloperidol and R121 and by tacrine 1.10(-4) mol/l. In the presence of tacrine 1.10(-7)-10(-5) mol/l or atropine the dopamine-induced contraction was significant. The data obtained suggested that tacrine 1.10(-4) mol/l inhibited the dopamine effects on gastric corpus smooth muscles. The effect was probably not dependent on its anticholinesterase activity or not realized through direct influence on D(2)-dopamine receptors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1358/mf.2004.26.2.800062 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!